Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
Bio-Rad Laboratories (BIO) Surpasses Q1 Earnings and Revenue Estimates
06:48pm, Thursday, 28'th Apr 2022
Bio-Rad (BIO) delivered earnings and revenue surprises of 76.43% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More
02:52pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.
Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More
12:18pm, Wednesday, 27'th Apr 2022
Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.
Bio-Rad (BIO) to Report Q1 Earnings: What's in the Cards?
01:02pm, Monday, 25'th Apr 2022 Zacks Investment Research
Robust uptake of dPCR products and a rebound in routine testing are likely to have contributed to Bio-Rad's (BIO) first-quarter top line.
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
02:19pm, Tuesday, 19'th Apr 2022 Zacks Investment Research
Investors are optimistic about Bio-Rad (BIO) owing to a recovery in most of its key global markets as well as an uptick in demand for COVID-related products.
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
12:02pm, Tuesday, 19'th Apr 2022
Investors are optimistic about Bio-Rad (BIO) owing to a recovery in most of its key global markets as well as an uptick in demand for COVID-related products.
Bio-Rad to Report First-Quarter Financial Results, Thursday, April 28, 2022
08:00am, Monday, 18'th Apr 2022
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the fir
Illumina (ILMN) Launches Genomic Solution Hub in Brazil
02:10pm, Wednesday, 13'th Apr 2022 Zacks Investment Research
Illumina's (ILMN) customers and partners in Brazil currently span basic research, applied markets to clinical labs and healthcare institutions.
Here's Why You Should Retain SmileDirectClub (SDC) For Now
01:04pm, Wednesday, 13'th Apr 2022 Zacks Investment Research
Investors are optimistic about SmileDirectClub's (SDC) series of cutting-edge innovation, strategic distribution and insurance partnerships.
Bruker (BRKR) Unveils New Imaging Tools for Cancer Research
12:54pm, Wednesday, 13'th Apr 2022 Zacks Investment Research
Bruker's (BRKR) latest innovation for cancer research is likely to strengthen the company's opportunities in proteomics and spatial biology.
Alcon (ALC) Stock Rallies 4.7% Since Posting Q4 Earnings Beat
02:36pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
Alcon (ALC) stock rallies on robust growth across all Surgical and Vision Care sales categories.
Here's Why You Should Hold on to Walgreens Boots (WBA) For Now
04:58pm, Monday, 11'th Apr 2022 Zacks Investment Research
Investors are optimistic about Walgreens (WBA) owing to the recent product launches.
Henry Schein (HSIC) Hits a New 52-Week High: What's Driving It?
12:50pm, Monday, 11'th Apr 2022 Zacks Investment Research
Investors are optimistic about Henry Schein (HSIC) owing to favorable dental business trends and a strong solvency position.
Here's Why You Should Hold on to Chemed (CHE) Stock For Now
03:18pm, Thursday, 07'th Apr 2022 Zacks Investment Research
Investors are optimistic about robust performance by Chemed's (CHE) Roto-Rooter arm.
Walgreens (WBA) Expands Medical Care Offerings in California
01:31pm, Thursday, 07'th Apr 2022 Zacks Investment Research
Walgreens' (WBA) new initiative is intended to reduce care gaps and advance care management by providing access to more affordable and convenient services.
